Lung Cancer | Specialty

Treating for Stage III NSCLC After Progression on Durvalumab

July 13th 2020

Durvalumab in Stage III NSCLC Based on Performance Status

July 13th 2020

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

July 13th 2020

Mediastinal Staging in Non–Small Cell Lung Cancer

July 13th 2020

Dr. Pennell on Challenges With NGS in Lung Cancer

July 10th 2020

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

SHAWL Study: A Sexual Health Assessment in Women With Lung Cancer

July 10th 2020

Data suggest that up to 95% of patients with lung cancer score below the fiftieth percentile on sexual function during and after completion of cancer-directed therapy.

Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

July 9th 2020

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Investigators Leverage Radiomics to Risk Stratify Patients With Early-Stage Lung Cancer

July 9th 2020

Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.

Trastuzumab Deruxtecan Shakes Up HER2-Mutated NSCLC Treatment Paradigm

July 7th 2020

Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting lung cancer data.

Roswell Park Is First Center in New York State to Implement Monarch Bronchoscopy Platform

July 7th 2020

Minimally invasive tool uses robotic technology to enable earlier, more accurate diagnosis of lung nodules.

FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 6th 2020

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

July 6th 2020

Second- and Third-Line Treatment for ES-SCLC

July 6th 2020

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

July 6th 2020

Expert Approaches to Treating Extensive Stage SCLC

July 6th 2020

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

July 6th 2020

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

July 6th 2020

ASCO 2020 Ushers in a Number of New Targeted Therapy Developments in NSCLC

July 5th 2020

Paul A. Bunn, Jr, MD, discusses how fam-trastuzumab deruxtecan-nxki could provide patients with metastatic non–small cell lung cancer who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy.

Brahmer Highlights Practice-Changing Data in HER2-Mutated NSCLC

July 3rd 2020

Julie R. Brahmer, MD, discusses the details of the DESTINY-Lung01 trial, as well as remaining questions that could be answered with further research.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon

July 2nd 2020

In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.